3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) has processed and analyzed the first batch of blood samples for the PRECISE prostate cancer trial at its new laboratory and corporate headquarters in the MaRS Discovery...
The online version of Fortune magazine has produced an article about the digital health revolution that discusses the contribution of Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant as a maintenance...
Titan Pharmaceuticals (NASDAQ:TTNP) and its marketing partner, closely-held Braeburn Pharmaceuticals, received a potential shot in the arm as the White House called for expanded access to treatment in the war on opioid...
Leerink upgraded Immunogen (NASDAQ:IMGN) to “outperform” from “market perform” and raised its price target to $8 from $2 based on a “higher level of conviction” on lead asset, mirvetuximab soravtansine, providing an...
Ladenburg Thalmann launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and price target of $55. The stock closed at $21.21 on April 12. Reata focuses on development of small molecule drugs for...
Roth Capital Partners initiated coverage of Auris Medical Holding (NASDAQ:EARS), a Swiss biopharmaceutical company developing therapeutics that address unmet medical needs in otology, with a “buy” rating and price...
IntelGenx (OTCQX:IGXT; TSXV:IGX) and Tetra Bio-Pharma (CSE:TBP; OTC:GRPOF) signed a definitive agreement to develop and commercialize a drug product containing the cannabinoid, Dronabinol, for the management of anorexia...
Leerink resumed coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating and a $16 price target, saying the company is well positioned to execute with multiple sources of upside. The stock closed at...
3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has successfully completed internal analytical assay validation for its Hodgkin’s lymphoma (HL) test (Telo-HL) according to FDA guidelines. Assay validation of Telo...
IntelGenx (OTCQX:IGXT; TSXV:IGX) announced that Eli Lilly granted IntelGenx’s VersaFilm an exclusive license for a tadalafil film product under its 6,943,166 erectile dysfunction (ED) dosing patent. Any exclusivity...